The CD-19-directed immunotoxin anti-B4-blocked ricin (anti-B4-bR) is currently in clinical trials for the treatment of Bcell malignancies. To explore the potential of using anti-B4-bR with chemotherapy protocols we tested the in vivo efficacy of the immunotoxin in combination with two multidrug chemotherapeutic regimens in severe combined immunodeficient (SCID) mice bearing disseminated tumors of the multidrug-resistant human B-cell lymphoma Namalwalmdr-1. In cytotoxicity studies in vitro, combinations of the immunotoxin with cisplatin produced supra-additive killing effects on both Namalwa and Namalwalmdr-1 cells, whereas antiBCbR combined with 4-hydroperoxy-cyclophosphamide caused additive killing of both cell lines. In vivo cyclophosphamide, cisplatin, vincristine, doxorubicin, and etoposide as single agents, were effective in prolonging the survival of SCID mice burdened with the Namalwa tumor, whereas only cyclophosphamide and cisplatin were effective on Namalwalmdr-1 tumors. Treatment of Namalwalmdr-l-bear-HE TREATMENT of lymphoma presents a challenge in T clinical oncology. Despite greater tumor cytoreduction achieved with increased doses and new combinations of chemotherapeutic agents,'" a large number of patients eventually re1ap~e.I.~ It is believed that one factor that limits the effectiveness of chemotherapy is the induction or intrinsic presence of tumor cells resistant to chemotherapy. Resistance to a wide variety of natural-product antineoplastic drugs, such as anthracyclines, Vinca alkaloids, etoposide, and actinomycin D is often because of the phenomenon known as multidrug resistance (MDR).5-7 MDR results from reduced intracellular drug accumulation in association with overexpression of the mdr gene encoding a membrane glycoprotein, termed P-glycoprotein, which mediates transport of drugs out of the cell^.^,^ One possible approach to overcoming drug resistance is to add new agents to the current treatment protocols that have different mechanisms of action and are not subject to cross-resistance. One emerging class of agents that may fit this role are immunotoxins, conjugates between monoclonal antibodies (MoAb) and potent toxins. Immunotoxins for the treatment of leukemias and lymphomas have already proceeded through clinical trials.'o*'' AntbB4-blocked ricin (anti-B4-bR) is an immunotoxin comprised of an anti-CD19 MoAb and a derivative of the toxic plant lectin ricin, called blocked ricin, which has its 0 1996 by The American Society of Hematology.
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ing mice with anti-WbR alone or with the drug combination CHOE (consisting of cyclophosphamide, vincristine, doxorubicin, and etoposide) alone increased the lifespan of the tumor-burdened mice by 58% and 7396, respectively. However, treatment with five daily bolus intravenous injections of anti-B4-bR followed by CHOE increased the lifespan by 173%. and 209' 0 of the mice were cured. The drug combination CCE (cyclophosphamide, cisplatin, and etoposide) alone could increase the lifespan of the Namalwalmdr-1 tumorburdened mice by 129% compared with untreated controls. Combination therapy with anti-B4-bR and CCE produced long-term cures in 5090 of the tumor-burdened mice. These results suggest that anti-W-bR in combination with current multidrug regimens may constitute a highly efficacious modality for the treatment of drug-resistant B-cell malignancies. 0 1996 by The American Society of Hematology.
galactose-binding sites blocked by covalently linked affinity ligands to minimize nonspecific toxicity. 1 2~1 3 The CD 19 antigen is expressed on normal and neoplastic B-cells, is Blineage restricted, and is detected early in B-cell ontogeny.l4.l5 Anti-B4-bR has shown cytotoxic potency, selectivity, and specificity in and has shown antitumor effects in SCID mouse models of human CD19' B-cell neop l a s m~.~~, "
Phase I dose escalation trials have shown safety and hinted at therapeutic efficacy for patients with relapsed and refractory B-cell neoplasms.'s-20
To develop a rationale for combining anti-BCbR with chemotherapeutic drug regimens we studied the interaction of the immunotoxin with doxorubicin and etoposide on the drug-sensitive Burkitt's lymphoma cell line Namalwa and the multidrug-resistant cell line Namalwdmdr-1 ." Anti-B4-bR showed synergistic killing with both of these drugs on the drug-sensitive and drug-resistant Namalwa cells in vitro. Treatment of the Namalwdmdr-1 xenografts in vivo with anti-B4-bR could completely reverse the drug-resistant phenotype and render the tumors as sensitive to either doxorubicin or etoposide as the Namalwa tumors." In this study these observations were extended to show that anti-B4-bR synergizes with the alkylating agents 4-hydroperoxy-cyclophosphamide (4-HC) and cisplatin in vitro on both Namalwa and Namalwdmdr-1 cells. Furthermore, it was found that anti-B4-bR could cure the Namalwdmdr-1 tumor-bearing animals when used in combination with multidrug regimens. The two drug regimens, CHOE and CCE, are experimental mimics of the clinically used regimens CHOEP',22.23 (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) and (ifosfamide, carboplatin, and etoposide) for treatment of recurrent or refractory non-Hodgkin's lymphoma.
MATERIALS AND METHODS
Anti-B4-bR was manufactured by ImmunoGen, Inc (Cambridge, MA) as described previ~usly.'~~'~ Vincristine was from Eli Lilly Co (Indianapolis, IN); doxorubicin from Immunoioxin and drugs. The Namalwdmdr-1 cell line was obtained through transfection of a human mdr-1 complementary DNA into the drug-sensitive Burkitt's lymphoma cell line Namalwa (ATCC CRL 1432) as described previously?' The Namalwdmdr-1 cell line was established from a clone growing in 50 nmoVL vincristine and that displayed cross-resistance to doxorubicin and etoposide."
Tumor cell lines were maintained as described previously.21 Both the drug-sensitive (1.7 X lo4 cells/well) and drug-resistant cells (1.2 X lo" cells/well) were incubated in the presence of various concentrations of anti-B4-bR, vincristine, doxorubicin, etoposide, cisplatin, or 4-HC for 72 hours. Surviving cells were then assayed by exposure to [3H]-thymidine (1 @/well) for 18 hours followed by counting the radioactivity incorporated into precipitated polymers. Cultures not exposed to drugs served as controls. Data were calculated as average counts per minute (cpm) from three experiments, each performed in 96-well plates using triplicate wells for each data point. Dose response curves were generated based on expressing cpm from treated cells as a fraction of cpm from untreated cells. IC,, values (defined as the concentration of drug that reduced [3H]dT by 63%) were determined graphically from relative survival curves. The in vitro data were analyzed using an adaptation of isobologram methodology used in the case where one agent is held constant as described previously?' Envelopes of additivity are derived from mode I additivity which accounts for potency differences between the two agents and mode I1 additivity, which is derived from the linear isoeffect relationship. Combinations producing an affect within the envelope boundaries of mode I and mode I1 are considered to be additive; those displaced to the left are greater than additive (ie, supra-additive), whereas those displaced to the right are less than additive tie, subadditive)?'
Female CB-17 SCID mice were obtained from Massachusetts General Hospital (Boston, MA) and were quarantined for at least 1 week. Animals were housed on a 12-hour light-dark cycle with food and water available ad libitum.
Cages, bedding, food, and water were sterilized. Water was acidified with IN hydrochloric acid to pH 2.4 to suppress growth of Pseudomonas. When the mice were 6 to 7 weeks of age, a suspension (0.2 mL) of Namalwdmdr-1 or Namalwa cells (4 X lo6 cells) was injected into a tail vein of the animals. This procedure resulted in a 100% tumor take with untreated or PBS-treated animals dying over approximately a 5 day range with a median survival time (MST) of about 25 days after tumor inoculation. Necropsy of tumor-bearing animals showed that the tumors have tropism for the ovaries, leptomeninges of the brain, bone marrow (BM) of the vertebra, dura mater of the spinal cord, and the muscles surrounding the spinal column.I6
Anti-BCbR was diluted appropriately with phosphate-buffered saline (PBS), pH 7.4, containing 0.1% human serum albumin (HSA), and injected into a tail vein of tumor bearing animals. The chemotherapeutic drugs vincristine, doxorubicin, etoposide, cyclophosphamide or cisplatin were administered intravenously (i.v.). Preliminary studies indicated that sequential treatments with anti-B4-bR and chemotherapeutic drugs were more effective than concurrent administration. Therefore, the combination therapies with anti-B4-bR and the multidrug regimens were conducted by treatment with the immunotoxin for 5 days starting on day 7 after tumor inoculation, followed by the multidrug regimens. To avoid excessive toxicity, the total doses of each agent were administered at about 45% to 65% of their maximum tolerated doses
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(MTDs) and the administration schedule altered so that the mice did not decrease in body weight more than 20% during the therapy. The MTD was defined as the maximum dose that could be administered to tumor-bearing mice without resulting in drug-related death. Optimal doses for the multidrug regimens were developed which gave maximal therapeutic benefit without deaths in the treated groups of mice. Control animals received no treatment, as we have observed previously that treatment with vehicle solution (PBS containing 0.1 % HSA) did not alter the survival of the tumor-bearing mice. A group receiving anti-B4-bR alone, as well as a group receiving the multidrug regimen alone at their respective optimal treatment schedules were included in each experiment as positive controls.
Each group contained 8 to 10 tumor-bearing animals. The endpoint for this study was animal survival. Animals were checked daily and animals that showed deteriorating and moribund condition were euthanized with C02. The survival of all mice was followed and an MST calculated for each group. The increase in life-span (JLS) was calculated by dividing the MST of a treatment group by the MST of the control group and is expressed as the percent increase over the life-span of the control animals. Statistical analysis was performed by the log-rank test and the Wilcoxon test2* at the 5% significance level.
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Combinations of anti-B4-bR and cisplatin or 4-HC on
Namalwa and Namalwdmdr-I cells. The sensitivity of Namalwa and Namalwdmdr-1 to anti-BCbR and chemotherapeutic drugs in vitro has been previously reported?l Namalwa cells were slightly more resistant than Namalwd mdr-1 cells to cisplatin with IC37 values of 250 nmol/L and 170 nmol/L, respectively, whereas both cell lines had an IC3, of 1 pmol/L towards 4-HC. Namalwa cells were also slightly more resistant than Namalwdmdr-1 cells to anti-B4-bR with IC37 values of 8 pmol/L and 4 pmoVL, respectively. Namalwdmdr-1 cells were approximately sixfold more resistant to doxorubicin and etoposide, and 40-fold more resistant to vincristine, showing a functional MDR phenotype.
To study the cytotoxic effects of anti-BCbR combined with cisplatin, Namalwa and Namalwdmdr-1 cells were incubated with anti-BbbR at concentrations of 10 pmol/L or 20 pmom and treated simultaneously with cisplatin at concentrations ranging from 0.1 to 1 . O pmol/L in the case of Namalwa cells and 0.1 to 0.5 pmol/L in the case of Namalwdmdr-1 cells. The cytotoxicity was measured by [3H]dT incorporation assays and the killing curves were subjected to isobologram analysis. The resultant isobolograms with the calculated envelopes of additivity are shown in Fig  1A (Namalwa) and Fig 1B (Namalwdmdr-1) . They indicate additive killing with the lower concentration of anti-B4-bR (10 pmol/L) for each cell line. At the higher concentration of anti-BCbR (20 pmoYL), the killing curves lie significantly outside the envelope of additivity in the area of supra-additivity.
The cytotoxic effects of combinations of anti-BCbR and 4-HC were assessed in a similar way. Namalwa and Namalwdmdr-1 cells were incubated with anti-B4-bR at concentrations of 10 p m o n and 20 p m o a . Each immunotoxin level was combined with 4-HC concentrations ranging from 0.5 to 3 pmol/L or 0.5 to 2 pmol/L for Namalwa and Namalwdmdr-1 cells, respectively. Isobolograms obtained are Anti-B4-bR and chemotherapy in treatment of the MDR tumor Namalwdmdr-I. The finding of additive or synergistic killing with anti-B4-bR and cisplatin or 4-HC on Namalwdmdr-1 cells, coupled with our previously reported synergism between Anti-B4-bR and doxorubicin, etoposide," or vincristine" on these cell lines in vitro and in vivo encouraged us to explore the possibility of combining anti-B4-bR with multidrug regimens consisting of both MDRrelated drugs and non-MDR-related drugs. In support of these studies, well-tolerated doses and efficacy data for all of the chemotherapeutic drugs as single agents had to be established for the Namalwa tumor model in SCID mice.
The therapeutic efficacy of anti-B4-bR and the chemotherapeutic drugs cyclophosphamide, cisplatin, vincristine, doxorubicin and etoposide, as single agents in the treatment of Namalwa or Namalwdmdr-1 xenograft tumors are summarized in Table 1 and Table 2 32%) , respectively. Namalwdmdr-1 tumor-bearing mice treated with five daily bolus iv injections of anti-B4-bR resulted in an MST value of 43 days which, when compared to the control MST of 25 days, corresponds to an ILS of 72% ( Table 2) . Vincristine, doxorubicin, or etoposide as single agents at their respective MTD did not show significant effects on survival of the Namalwdmdr-1 tumor-burdened mice. However, treatment with both cyclophosphamide and cisplatin, drugs that are not subject to MDR, were effective in prolonging survival of treated animals with MSTs of 48 days (ILS = 92%) and 32 days (ILS = 28%), respectively. Noteworthy in this study as well as in our previous study is that the Namalwdmdr-1 tumor is more responsive to anti-BCbR than the drug-sensitive Namalwa tumor.
Combination therapies of the MDR tumor Namalwdindr-1 with anti-B4-bR and multidrug regimens. We next explored the possibility of combining anti-B4-bR with multidrug regimens, which would be used in a clinical setting and consist of the drugs used above. Based on the data with reversal of drug resistance in the Namalwdmdr-1 cells, and because synergism with the alkylating drug 4-HC and cisplatin was observed on both Namalwa and Namalwdmdr-1 cells, two multidrug regimens, CHOE and CCE were investigated in SCIDNamalwdmdr-1 model.
In the anti-B4-bR-CHOE study, Namalwdmdr-1 tumorbearing mice were treated either with anti-BCbR alone, with CHOE alone, or with anti-BCbR plus CHOE (Fig 3) . Although treatment with an optimal dose of the multidrug regimen alone or treatment with anti-BCbR alone (50 pg/kg/d X 5, 67% of the MTD) could significantly increase survival of the tumor-burdened mice (MSTs = 41 and 45 days, respectively, compared to the MST of 26 days for the control group; ILS of 58% and 73%, respectively; P < .001), there were no cures. However, treatment with anti-B4-bR followed by the same doses of CHOE resulted in an MST of 71 days for treated mice (ILS = 173%) and produced long-term cures in 2 of 10 mice (animals survived over 180 days at which time the experiment was terminated , Fig 3) . When gross and histopathologic examinations were performed, neither of these mice had any sign of tumor.
An even better result was observed in mice when treatment with anti-BCbR was combined with the CCE regime (Fig  4) . In this study Namalwdmdr-1 tumor-bearing mice were treated either with anti-BCbR alone, with the CCE regimen alone, or with anti-BCbR plus CCE. Treatment with the optimal dose of CCE alone was effective in increasing the MST of the animals from 24 days (control group) to 55 days (ILS = 129%; P < .0005). Anti-B4-bR alone increased the MST to 40 days (ILS = 67%, P < .001). The combination therapy of anti-BCbR plus CCE was extremely effective and produced long-term cures in 50% of the tumor-burdened mice. Again these mice showed no signs of tumor, confirmed by histopathologic examination on day 180. In previous studies, we have shown that anti-B4-bR could reverse multidrug resistance of Namalwdmdr-1 cells to doxorubicin, etoposide, and vincristine in vitro and in v~v o .~' .~~ In the current study anti-B4-bR produced greater than additive cytotoxicity with the antitumor alkylating drugs 4-HC and cisplatin against both drug-sensitive and drug-resistant tumor cells. The observation that synergistic killing was obtained with these agents on both Namalwa and Namalwdmdr-1 cells showed that this synergism is independent of the MDR phenotype. This coupled with our previous observation of synergistic cytotoxicity between anti-B4-bR and doxorubicin, etoposide, or vincristine against MDR expressing cells21.29 may suggest that anti-BCbR can synergize with drugs by downregulating several drug-resistance related proteins (such as P-glycoprotein, glutathione synthetase, and glutathione S-transferase) through its action of inhibiting protein synthesis. This indicates that the immunotoxin could be used to good effect when added to chemotherapeutic regimens consisting of both MDR-related and non-MDRrelated drugs.
When it was established that anti-B4-bR could interact positively with these different drugs, two multidrug regimens, which are used for the treatment of refractory nonHodgkin's lymphoma, were modeled in animals. It is likely that a combination study with the immunotoxin and multidrug regimens would be a more realistic model for the clinical situation and would provide important information for the design of a clinical trial. The combination therapies of anti-B4-bR plus the single agents vincristine, doxorubicin, or etoposide2'.:' or multidrug regimens (without need to reduce the drug doses) could be tolerated by the tumor-bearing mice. However, in the combination therapies, the intervals of administration of the chemotherapeutic drugs had to be prolonged, because the initial studies showed that using the same treatment schedules as single agent treatment caused unacceptable systemic toxicity as shown by a body weight loss of >20% with several animals dying of toxicity.
An interesting feature of these studies was that although the drug combinations alone without the immunotoxin were effective therapy against the Namalwdmdr-1 tumor by significantly extending the lifespan of the mice, they could still be improved upon by the immunotoxin anti-B4-bR to bring about cures. This shows how existing drug combinations could be further improved by adding a therapeutic agent such as anti-B4-bR, which does not have overlapping toxicity and is not subject to the same drug-resistant mechanisms as the agents in the existing combinations.
The importance of overcoming the MDR phenotype for a successful cancer treatment has been firmly e~tablished.~.'.~' 
